United States·Stock·NasdaqAlnylam Pharmaceuticals, Inc. (ALNY)
Health Care · Biotechnology · North America
Price in USD, last 5 years
- Last price
- $225.96 (Oct 22, 2026)
- 1-year return
- -51.4%
- 3-year annual return
- +11.8%
- 5-year annual return
- +2.6%
- 1-year volatility
- 48.2%
- Max drawdown (5Y)
- -58.2%
- Market cap (approx.)
- US$30.2B
- History available
- since Jan 2, 2014
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) is a stock from the United States that trades on Nasdaq in USD. It operates in the health care sector, Biotechnology industry. It's part of the Nasdaq-100.
Over the last year its price fell 51.4% in USD, with annual volatility of 48%: a quite volatile asset. Its worst drop over the last five years was 58.2% from a peak.
How does it fit into a portfolio? What matters is not just its risk on its own, but how much it moves together with your other assets. Add it to your list and the optimizer will show you what weight the model would give it and why.
Other health care assets in North America
| Asset | 1 year | 1Y return | Volatility | Market cap | |
|---|---|---|---|---|---|
Eli Lilly and CompanyLLY · Stock · Health Care | +61.9% | 35% | US$1.17T | ||
Johnson & JohnsonJNJ · Stock · Health Care | +39.8% | 20% | US$635.3B | ||
AbbVie Inc.ABBV · Stock · Health Care | +27.9% | 26% | US$502.9B | ||
UnitedHealth Group IncorporatedUNH · Stock · Health Care | +20.4% | 35% | US$379.9B | ||
Merck & Co., Inc.MRK · Stock · Health Care | +79.3% | 30% | US$376.8B | ||
Thermo Fisher Scientific Inc.TMO · Stock · Health Care | +20.9% | 29% | US$251.6B | ||
Amgen Inc.AMGN · Stock · Health Care | +54.9% | 30% | US$241.3B | ||
Gilead Sciences, Inc.GILD · Stock · Health Care | +31.5% | 27% | US$193.0B |
Disclaimer: Educational and simulation tool. It is not investment advice or a personalized recommendation. Past performance does not guarantee future results. Data for educational purposes; it may be delayed or contain errors.